Showing 61-70 of 9358 results for "".
- Dermatologists React to Reports of Adverse Events in Filler Patients Who Got COVID-19 Vaccineshttps://practicaldermatology.com/news/report-covid-19-vaccines-and-dermatology/2460648/As case reports of facial swelling in patients with a history of dermal filler treatment who received Moderna’s COVID-19 vaccine accrue, dermatologists are devising new protocols for how to best address this potential phenomenon, including the optimal timing of fillers and vaccines, updated consent…
- Allergan Appoints Douglas S. Ingram as Presidenthttps://practicaldermatology.com/news/20130702-allergan_appoints_douglas_s_ingram_as_president/2459504/Douglas S. Ingram was appointed as President of Allergan. In this role, Mr. Ingram will lead the company's global commercial operations, with responsibility for the company's broad portfolio of pharmaceutical, consumer, and medical device products including facial aesthetics products such as BOTOX®…
- Leo Pharma's Adbry Reduces S. aureus Skin Colonization in Kids With ADhttps://practicaldermatology.com/news/leo-pharmas-adbry-reduces-s-aureus-skin-colonization-in-kids-with-ad/2461616/Leo Pharma’s Adbry (tralokinumab-ldrm) significantly reduced the abundance of Staphylococcus aureus in the lesional and non-lesional skin of adolescents with atopic dermatitis (AD) after 16 weeks, according to new data presented at the American Academy of Dermatology (AAD) 2023 Annual Meeting. At…
- USPTO Grants Patents to TOOsonix A/S for HIFU Technologies in Dermatologyhttps://practicaldermatology.com/news/uspto-grants-patents-to-toosonix-as-for-hifu-technologies-in-dermatology/2461420/The United States Patent and Trademark Office (USPTO) granted TOOsonix A/S patents regarding its key high-intensity focused ultrasound (HIFU) technologies for dermatology The U.S. patent and already granted patents in Europe and China to complete the first phase of securing intellectual property ri…
- Don't Forget Leprosy: Group Marks 150th Anniversary of Dr. Hansen's Discovery of M. lepraehttps://practicaldermatology.com/news/dont-forget-leprosy-group-marks-150th-anniversary-of-dr-hansens-discovery-of-m-leprae/2461573/The University of Bergen, Norway and Sasakawa Leprosy (Hansen's Disease) Initiative will mark the 150th anniversary of Dr. Gerhard Armauer Hansen's discovery of the leprosy bacillus, M. leprae, in 1873. They plan to hold an event in Bergen and launch a commemorative webcast on Feb. 28, 2023. Dr.…
- SBS Part 1: The Medical Dermatology Summit to Kick Off February 4https://practicaldermatology.com/news/sbs-part-1-the-medical-dermatology-summit-to-kick-off-february-4/2460659/SBS Part I: The Medical Dermatology Summit will offer complimentary direct access to leading academic experts, clinical leaders, researchers, and more through live-streamed and interactive sessions as well as on-demand content, next month. Presented by LiVDerm, The Medical Dermatology Summit is th…
- High Kissability Marks for Restylane Kysse in New Phase 4 Studyhttps://practicaldermatology.com/news/high-kissability-marks-for-restylane-kysse-in-new-phase-4-study/2460465/In a recent first-of-its-kind phase IV, Kissability study for an injectable hyaluronic acid (HA) lip filler, subject satisfaction as well as partner satisfaction were evaluated following treatment with Restylane Kysse. Many consumers report they often keep their lip treatments a secret and have con…
- Allergan Vet Julian S. Gangolli Joins Revance's Board of Directorshttps://practicaldermatology.com/news/allergan-vet-julian-s-gangolli-joins-revances-board-of-directors/2458508/Julian S. Gangolli, President, North America, of GW Pharmaceuticals plc, is now on Revance's Board of Directors and will serve as a member of the Audit Committee, effective July 1, 2016. He will help Revance progress toward regulatory approval and commercialization of RT002 injectable, a novel n…
- Cutera: Aviclear Hits 1,000 Treatment Markhttps://practicaldermatology.com/news/cutera-aviclear-hits-1000-treatment-mark/2461333/More than 1,000 AviClear laser acne treatments have been performed in the United States, Cutera reports. AviClear is FDA-cleared for the treatment of mild, moderate and severe acne. Additionally, AviClear recently received approval from Health Canada for the treatment of all severities of acne as …
- Hoth Therapeutics, Inc.’s BioLexa in AD: So Far, So Safehttps://practicaldermatology.com/news/hoth-therapeutics-incs-biolexa-in-ad-so-far-so-safe/2460853/Hoth Therapeutics, Inc.’s BioLexa was well tolerated with no serious adverse events and no drug-related treatment-emergent adverse events observed, according to the safety results in Cohort 1 of its first in human clinical trial of the BioLexa platform to treat atopic dermatitis. BioLexa has been…